サポート情報

ウェビナー(オンラインセミナー)

記事ID : 39095

Mabtech AB社 オンラインセミナー「FluoroSpot and ELISpot as tools in COVID-19 research」


1986年に設立されたマブテック社は、高品質なカスタムメイドのモノクローナル抗体を生産するバイオテクノロジー企業です。80年代後半に開発して以来、マブテック社はELISpot技術の最前線におり、ELISpotアッセイに特に適した抗体の開発・製造に取り組んでいます。

FluoroSpot and ELISpot as tools in COVID-19 research

webinar-mabtech-ab-mab_01.png

  • 概要:
    • The ELISpot method, originally developed to quantify the number of immunoglobulin-secreting cells, has evolved to be one of the most sensitive, high-throughput and commonly used techniques to monitor cell mediated immune responses by measuring the secretion of cytokines. It is used for studies of immune responses in a wide range of diseases, e.g. allergy, infections, autoimmune diseases and cancer. The IFN-g ELISpot assay is considered a standard tool to evaluate antigen-specific T cell immunity during the development of vaccine candidates and monitoring of new vaccines. Although ELISpot measures secretion of one cytokine, it can be used to measure secretion of up to four cytokines in one well with a slightly different approach called FluoroSpot, using fluorescent labels.
      FluoroSpot allows for analysis of polyfunctional T-cells producing two or more cytokines simultaneously, the relative amount of cytokine secreted per cell can also be determined. FluoroSpot can also be used to analyze the frequency of IgG producing, antigen specific memory B-cells recognizing up to four different antigens in the same well.
      The SARS-CoV-2 pandemic has triggered a massive global effort to produce a vaccine, monitor natural immune responses triggered by SARS-CoV-2 infection and evaluate cross-reactive T and B-cell responses triggered by other coronavirus infections. ELISpot and FluoroSpot assays have been a integral part of the analysis package used in the battle against SARS-CoV-2.
  • 演者:Dr. Bartek Makower, Head of R&D from Mabtech AB, Sweden
  • 言語:英語
  • 日時:2020年10月29日 9.30 - 11.00 am (GMT +2)
  • 配信形式:Zoom

このWEBセミナーは終了しました。


© COSMO BIO